Arsanis, which is developing antibodies designed to prevent serious infectious diseases, announced terms for its IPO on Monday.
The Waltham, MA-based company plans to raise $50 million by offering 3.1 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Arsanis would command a fully diluted market value of $186 million.
Arsanis was founded in 2010 and plans to list on the Nasdaq under the symbol ASNS. Citi, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of November 13, 2017.
